RecruitingPhase 2NCT05597345

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Selinexor for the Treatment of Patients with Intermediate and High-Risk Smoldering Multiple Myeloma

Sponsor

University of Rochester

Enrollment

15 participants

Start Date

Aug 21, 2023

Study Type

INTERVENTIONAL

Conditions

Smoldering Multiple Myeloma

Summary

Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient population has a much lower risk. This is a clinical trial investigating the use of low-dose selinexor in patients with intermediate to high-risk smoldering multiple myeloma. The investigators hypothesize that the use of selinexor in intermediate to high risk smoldering myeloma patients will help to delay progression of disease to symptomatic multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a drug called selinexor for people with smoldering multiple myeloma (SMM), a condition where abnormal plasma cells are present in the bone marrow but haven't yet caused organ damage. It's an early-stage blood cancer that can progress to active multiple myeloma. Researchers want to see if treating it early can delay or prevent progression. **You may be eligible if...** - You are 18 or older - You have been diagnosed with intermediate or high-risk smoldering multiple myeloma - Your disease meets specific blood or bone marrow criteria for SMM - You have not yet developed bone damage, kidney problems, high calcium, or severe anemia from the disease **You may NOT be eligible if...** - Your smoldering myeloma has already progressed to active multiple myeloma - You have serious organ damage caused by the myeloma - You have a history of certain other cancers or serious health conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSelinexor

Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma

Locations(1)

University of Rochester

Rochester, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05597345

Related Trials

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT022695927 locations

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

NCT074467771 location

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

NCT056408438 locations

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

NCT063831434 locations

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

NCT053616941 location